lignans has been researched along with icariin* in 3 studies
1 review(s) available for lignans and icariin
Article | Year |
---|---|
Pharmacological activity of cardiovascular agents from herbal medicine.
Some of the active phytochemicals in herbal medicine are finding therapeutic use. For example, patients with heart disease are reported to benefit from treatment with herbal medicine with fewer side effects. Previous studies showed the inhibitory effects of tetramethylpyrazine, an active component of medicinal herb, on phosphodiesterase that is associated with heart disease and the cardio-protective effects of other herbal medicine that was used to protect ischemia-reperfusion injury of rat hearts. Individual herbal medicines show antipyretic, analgesic and anti-inflammatory and anti-cancer effects. In addition to sharing many therapeutic activities, the active components of herbal medicine are also used in nutrient supplement for cardiovascular disease. Numerous in vitro studies of herbal medicine on different cell lines and in vivo study of herbal medicine have been reported. However, the mechanism of actions remains unclear. The present review aims to give an overview of the recent development of herbal medicine in treatment of cardiovascular disease, and covers the possible mechanism of action of some of active principles. The study will provide insights into drug action and demonstrate the therapeutic benefits of herbal medicine for the treatment of cardiovascular disease. Topics: Alkaloids; Astragalus propinquus; Biphenyl Compounds; Cardiovascular Agents; Drugs, Chinese Herbal; Flavonoids; Glycyrrhizic Acid; Herbal Medicine; Humans; Lignans; Phenanthrenes; Pyrazines | 2007 |
2 other study(ies) available for lignans and icariin
Article | Year |
---|---|
[Research on the preparative method of Arctigenin].
To research on the preparation of Arctigenin in vitro.. Took enzyme concentration, time course and substrate concentration as investigation factors, used Box-Behnken design-response surface methodology to optimize the enzyme hydrolysis path of Arctigenin.. The best operational path for Arctigenin was as follows: the temperature was 50 degrees C, pH was 4.8, enzyme concentration was 0.44 U/mL, time course was 46.81 min, substrate concentration was 0.29 mg/mL, the conversion rate was 90.94%.. This research can be regarded as a referencein preparing Arctigenin in vitro. Topics: Arctium; Flavonoids; Furans; Glucosides; Hydrogen-Ion Concentration; Hydrolysis; Lignans; Technology, Pharmaceutical; Temperature; Time Factors | 2012 |
Icariin: a potential osteoinductive compound for bone tissue engineering.
To effectively treat bone diseases using bone regenerative medicine, there is an urgent need to develop safe and cheap drugs that can potently induce bone formation. Here, we demonstrate the osteogenic effects of icariin, the main active compound of Epimedium pubescens. Icariin induced osteogenic differentiation of preosteoblastic cells. The combination of icariin and a helioxanthin-derived small compound synergistically induced osteogenic differentiation of MC3T3-E1 cells to a similar extent to bone morphogenetic protein-2. Icariin enhanced the osteogenic induction activity of bone morphogenetic protein-2 in a fibroblastic cell line. Mineralization was enhanced by treatment with a combination of icariin and calcium-enriched medium. The in vivo anabolic effect of icariin was confirmed in a mouse calvarial defect model. Eight-week-old male C57BL/6N mice were transplanted with icariin-calcium phosphate cement (CPC) tablets or CPC tablets only (n = 5 for each), and bone regeneration was evaluated after 4 and 6 weeks. Significant new bone formation was observed in the icariin-CPC group at 4 weeks, and the new bone thickness had increased by 6 weeks. Obvious blood vessel formation was observed in the icariin-induced new bone. Treatment of senescence-accelerated mouse prone 1 and senescence-accelerated mouse prone 6 models further demonstrated that icariin was able to enhance bone formation in vivo. Therefore, icariin is a strong candidate for an osteogenic compound for use in bone tissue engineering. Topics: Animals; Bone Cements; Bone Morphogenetic Protein 2; Bone Regeneration; Calcification, Physiologic; Drug Synergism; Epimedium; Flavonoids; Lignans; Male; Mice; NIH 3T3 Cells; Skull Fractures; Time Factors | 2010 |